CAMBRIDGE, Mass., March 27, 2023 Cyclerion Therapeutics, Inc. , a clinical-stage biopharmaceutical company on a mission to develop treatments for serious diseases, today announced that the U.S.. | March 27, 2023
EQS-News: HepaRegeniX GmbH / Key word(s): Personnel HepaRegeniX appoints Dr. Andreas Busch as Senior Advisor 23.11.2022 / 09:00 CET/CEST The issuer is solely responsible for the content of this announcement. HepaRegeniX appoints Dr. Andreas Busch as Senior Advisor Tübingen (Germany), November 2.
Form SC 13D Cyclerion Therapeutics, Filed by: Slate Path Capital LP streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Recent positive MELAS clinical study data drive urgency to deliver potential first-ever therapy for patients with rare, genetic mitochondrial diseases .